Brusatol

Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent[1]. Brusatol increases cellular apoptosis[2].

Product Specifications

CAS Number

[14907-98-3]

Product Name Alternative

NSC 172924

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Keap1-Nrf2

Type

Natural Products

Related Pathways

Apoptosis; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Brusatol.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

CC([C@](C[C@@](O1)2[H])3[H])=C(O)C(C[C@]3(C)[C@]4([H])[C@]2(CO[C@@]5([C@@H](O)[C@@H]4O)C(OC)=O)[C@@]5([H])[C@@H](OC(/C=C(C)/C)=O)C1=O)=O

Molecular Formula

C26H32O11

Molecular Weight

520.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Dongmei Ren, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011 Jan 25;108 (4) :1433-8.|[2]Hai-Ming Chen, et al. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int J Mol Med. 2018 Mar;41 (3) :1447-1454. |[3]Adedamola Olayanju, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015 Jan;78:202-12.